Combinatorial biomarker expression in breast cancer |
| |
Authors: | Emad A Rakha Jorge S Reis-Filho Ian O Ellis |
| |
Institution: | (1) Department of Histopathology, Nottingham University Hospitals NHS Trust, Nottingham City Hospital, Hucknall Road, Nottingham, NG5 1PB, UK;(2) Molecular Pathology Laboratory, The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, Fulham Road, London, UK |
| |
Abstract: | Current clinical management of breast cancer relies on the availability of robust clinicopathological variables and few well-defined
biological markers. Recent microarray-based expression profiling studies have emphasised the importance of the molecular portraits
of breast cancer and the possibility of classifying breast cancer into biologically and molecularly distinct groups. Subsequent
large scale immunohistochemical studies have demonstrated that the added value of studying the molecular biomarker expression
in combination rather than individually. Oestrogen (ER) and progesterone (PR) receptors and HER2 are currently used in routine
pathological assessment of breast cancer. Additional biomarkers such as proliferation markers and ‘basal’ markers are likely
to be included in the future. A better understanding of the prognostic and predictive value of combinatorial assessment of
biomarker expression could lead to improved breast cancer management in routine clinical practice and would add to our knowledge
concerning the variation in behaviour and response to therapy. Here, we review the evidence on the value of assessing biomarker
expression in breast cancer individually and in combination and its relation to the recent molecular classification of breast
cancer. |
| |
Keywords: | |
本文献已被 SpringerLink 等数据库收录! |
|